StockMarketWire.com - Cell-based therapies developer MaxCyte said it had appointed Amanda L. Murphy as its chief financial officer.

She would replace long-serving CFO Ron Holtz, who would become senior vice president and chief accounting officer.

Murphy was previously managing director of BTIG and had also been a partner and healthcare analyst at William Blair & Company.


At 9:05am: [LON:MXCT] MaxCyte Inc share price was 0p at 330p



Story provided by StockMarketWire.com